Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

422 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Trial of Pimavanserin in Dementia-Related Psychosis.
Tariot PN, Cummings JL, Soto-Martin ME, Ballard C, Erten-Lyons D, Sultzer DL, Devanand DP, Weintraub D, McEvoy B, Youakim JM, Stankovic S, Foff EP. Tariot PN, et al. N Engl J Med. 2021 Jul 22;385(4):309-319. doi: 10.1056/NEJMoa2034634. N Engl J Med. 2021. PMID: 34289275 Clinical Trial.
Pimavanserin and dementia-related psychosis.
Tariot PN, Ballard C, Devanand DP, Cummings JL, Sultzer DL. Tariot PN, et al. Lancet Neurol. 2022 Feb;21(2):114-115. doi: 10.1016/S1474-4422(21)00466-X. Lancet Neurol. 2022. PMID: 35065031 No abstract available.
Pimavanserin: Potential Treatment For Dementia-Related Psychosis.
Cummings J, Ballard C, Tariot P, Owen R, Foff E, Youakim J, Norton J, Stankovic S. Cummings J, et al. J Prev Alzheimers Dis. 2018;5(4):253-258. doi: 10.14283/jpad.2018.29. J Prev Alzheimers Dis. 2018. PMID: 30298184 Free PMC article. Review.
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.
Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, Lebowitz BD, Lyketsos CG, Ryan JM, Stroup TS, Sultzer DL, Weintraub D, Lieberman JA; CATIE-AD Study Group. Schneider LS, et al. Among authors: tariot pn. N Engl J Med. 2006 Oct 12;355(15):1525-38. doi: 10.1056/NEJMoa061240. N Engl J Med. 2006. PMID: 17035647 Free article. Clinical Trial.
Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease.
Egan MF, Kost J, Tariot PN, Aisen PS, Cummings JL, Vellas B, Sur C, Mukai Y, Voss T, Furtek C, Mahoney E, Harper Mozley L, Vandenberghe R, Mo Y, Michelson D. Egan MF, et al. Among authors: tariot pn. N Engl J Med. 2018 May 3;378(18):1691-1703. doi: 10.1056/NEJMoa1706441. N Engl J Med. 2018. PMID: 29719179 Free PMC article. Clinical Trial.
Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease.
Egan MF, Kost J, Voss T, Mukai Y, Aisen PS, Cummings JL, Tariot PN, Vellas B, van Dyck CH, Boada M, Zhang Y, Li W, Furtek C, Mahoney E, Harper Mozley L, Mo Y, Sur C, Michelson D. Egan MF, et al. Among authors: tariot pn. N Engl J Med. 2019 Apr 11;380(15):1408-1420. doi: 10.1056/NEJMoa1812840. N Engl J Med. 2019. PMID: 30970186 Free PMC article. Clinical Trial.
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Salloway S, et al. N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839. N Engl J Med. 2014. PMID: 24450891 Free PMC article. Clinical Trial.
422 results